{
    "clinical_study": {
        "@rank": "107672", 
        "acronym": "ETS6103-003", 
        "arm_group": [
            {
                "arm_group_label": "ETS6103 (low dose)", 
                "arm_group_type": "Experimental", 
                "description": "ETS6103 (low dose) extended release tablets (encapsulated) taken once daily orally for the  duration of randomised phase of the study (8 weeks)."
            }, 
            {
                "arm_group_label": "ETS6103 (high dose)", 
                "arm_group_type": "Experimental", 
                "description": "ETS6103 (high dose) extended release tablets (encapsulated) taken once daily orally for the duration of randomised phase of the study (8 weeks)."
            }, 
            {
                "arm_group_label": "Amitriptyline", 
                "arm_group_type": "Active Comparator", 
                "description": "Amitriptyline tablets (encapsulated) Standard dosing regime"
            }, 
            {
                "arm_group_label": "Lead-in phase", 
                "arm_group_type": "No Intervention", 
                "description": "Citalopram tablets:\nStandard dosing regime"
            }
        ], 
        "brief_summary": {
            "textblock": "To demonstrate that the antidepressant activity of ETS6103 is not inferior to amitriptyline\n      in subjects who have an unsatisfactory response to / are resistant to treatment with SSRIs."
        }, 
        "brief_title": "Safety and Efficacy Study Comparing ETS6103 With Amitriptyline in the Treatment of Major Depressive Disorder (MDD)", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Major Depressive Disorder", 
        "condition_browse": {
            "mesh_term": [
                "Depressive Disorder", 
                "Depression", 
                "Depressive Disorder, Major"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Signed informed consent\n\n          -  Male or female\n\n          -  Age 18-65 years inclusive\n\n          -  Subjects with a current episode of moderate to severe Major Depressive Disorder\n             meeting the criteria of Diagnostic and Statistical Manual of Mental Disorders (DSM)\n             IV -TR and documented using the brief structured interview Mini International\n             Neuropsychiatric Interview (MINI) version 5.0 and with a minimum duration of two\n             weeks and a maximum of twelve months\n\n          -  Minimum Hamilton Depression Scale (HAM-D) 17 items total score of 18 at screening and\n             \u226512 at the end of the lead-in phase prior to randomization.\n\n          -  Male subjects with female partners of child-bearing potential and female subjects who\n             are neither surgically sterilized nor post-menopausal (defined as no menses for one\n             year or an follicle stimulating hormone (FSH) value >40 IU/L) will be required to use\n             effective contraception throughout the study and for 30 days after. The following\n             contraceptive methods are acceptable: hormonal (e.g. oral, injection, transdermal\n             patch, implant, cervical ring), barrier (e.g. condom or diaphragm with spermicidal\n             agent), intrauterine system (IUS) or intrauterine device (IUD). If hormonal\n             contraceptives are used by female subjects they must be established for 6 weeks\n             before the first administration of test product. Male sterilization is considered an\n             acceptable form of contraception if the appropriate post-vasectomy documentation\n             (absence of sperm) is provided. Sexual abstinence is considered acceptable if this is\n             in line with the preferred and usual lifestyle of the subject; periodic abstinence\n             (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are\n             not acceptable methods of contraception.\n\n          -  Able to understand and comply with the requirements of the study as judged by the\n             investigator\n\n        Exclusion Criteria:\n\n          -  Considered by the investigator to be at significant risk of suicide or scoring 5 or\n             more on the Montgomery Asberg Depression Rating Scale (c) question 10\n\n          -  Significant other psychiatric illness which would interfere with trial assessments\n             co-morbid generalized anxiety disorder (GAD) and panic disorder will be permitted\n             where MDD is considered the primary diagnosis\n\n          -  Significant physical illness which would interfere with trial assessments\n\n          -  Recent (within 1 week of screening) antidepressants (except for fluoxetine [within 4\n             weeks of screening] and St John's Wort or Monoamine oxidase inhibitors (MAOI) [within\n             14 days of screening]),\n\n          -  Benzodiazepine or any other psychotropic medication including lithium or other mood\n             stabilizers within 1 week of screening\n\n          -  Oral anticoagulant therapy within one month of screening\n\n          -  Formal psychotherapy or alternative treatments for one week prior to screening or\n             during the study\n\n          -  Reduced hepatic function defined as liver enzyme levels \u22652.5 times upper limit of\n             normal\n\n          -  Renal insufficiency defined as creatinine clearance <30 mL/min\n\n          -  Epilepsy\n\n          -  Uncontrolled hypothyroidism\n\n          -  Uncontrolled hypertension\n\n          -  Acute porphyria\n\n          -  Urinary retention, prostatic hypertrophy, narrow angle glaucoma or increased\n             intraocular pressure or any other clinically relevant contraindication stated in the\n             Summary of Product Characteristics (SmPC) for citalopram, tramadol or amitriptyline\n\n          -  History of significant cardiac dysrhythmia or history of myocardial infarction within\n             1 year prior to screening\n\n          -  Significant history of alcohol or substance abuse\n\n          -  Regular alcohol intake above the recommended United Kingdom (UK) guideline of 4 units\n             per day for males or 3 units per day for females\n\n          -  Pregnant or lactating women\n\n          -  Known hepatitis B or C or human immunodeficiency virus (HIV) or syphilis\n             seropositivity.\n\n          -  A corrected QT interval of >470ms for female subjects of >450ms for male subjects,\n             calculated using the QTcB (Bazett Correction Formula) , or second degree or higher\n             heart block on an electrocardiography (ECG) recording, at screening.\n\n          -  Allergy to the study drugs or excipients\n\n          -  Treatment with another investigational medicinal product within the 30 days prior to\n             screening."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "162", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02014363", 
            "org_study_id": "ETS6103-003", 
            "secondary_id": "2013-000719-26"
        }, 
        "intervention": [
            {
                "arm_group_label": "ETS6103 (low dose)", 
                "intervention_name": "ETS6103 (low dose)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "ETS6103 (high dose)", 
                "intervention_name": "ETS6103 (high dose)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Amitriptyline", 
                "intervention_name": "Amitriptyline", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Amitriptyline", 
                "Amitriptyline, perphenazine drug combination", 
                "Serotonin Uptake Inhibitors"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 31, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Glasgow", 
                    "country": "United Kingdom", 
                    "state": "Scotland", 
                    "zip": "G20 OXA"
                }, 
                "name": "CPS Research"
            }, 
            "investigator": {
                "last_name": "Alan G Wade, MBChB", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "4", 
        "official_title": "Double Blind, Non-inferiority Study to Evaluate the Antidepressant Activity of ETS6103 Compared With Amitriptyline in the Treatment of Major Depressive Disorder (MDD) in Patients Who Have an Unsatisfactory Response to Selective Serotonin Re-uptake Inhibitors (SSRIs).", 
        "overall_contact": {
            "email": "alan@cpsresearch.co.uk", 
            "last_name": "Alan G Wade, MBChB", 
            "phone": "0044-141-946-7888"
        }, 
        "overall_official": {
            "affiliation": "CPS Research", 
            "last_name": "Alan G Wade, MBChb", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The MADRS will be measured at every visit", 
            "measure": "The mean difference in baseline-adjusted (Montgomery-Asberg Depression Scale) MADRS score at the end of treatment.", 
            "safety_issue": "No", 
            "time_frame": "8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02014363"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The mean difference in baseline-adjusted MADRS score at weeks 1, 2, 4 and 6. Percentage of subjects with remission defined as \u2264 10 on the MADRS at the end of treatment.\nPercentage of responders defined as \u2265 50% decrease from baseline in the MADRS at the end of treatment (week 8)", 
                "measure": "Assessment of MADRS score throughout the randomised study period", 
                "safety_issue": "No", 
                "time_frame": "Randomised treatment weeks 1, 2, 4, 6 and 8"
            }, 
            {
                "description": "The mean difference in baseline-adjusted CGI severity at week 8. The mean difference in CGI improvement at weeks 1, 2, 4, 6 and 8.", 
                "measure": "Assessment of Clinical Global Impression (CGI) of Severity / Improvement Scale", 
                "safety_issue": "No", 
                "time_frame": "Randomised treatment weeks 1 to 8"
            }
        ], 
        "source": "e-Therapeutics PLC", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "e-Therapeutics PLC", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}